{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:48:54Z","timestamp":1794937734321,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00556-1","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:30:10Z","timestamp":1755505810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics and outcomes of anti-MDA5 dermatomyositis: a retrospective study"],"prefix":"10.1186","volume":"9","author":[{"given":"Tulaton","family":"Sodsri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tananchai","family":"Petnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitiporn","family":"Suwatanapongched","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayanin","family":"Nitiwarangkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nantakarn","family":"Pongtarakulpanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pintip","family":"Ngamjanyaporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"7","key":"556_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis: (First of two Parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"key":"556_CR2","doi-asserted-by":"publisher","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.","journal-title":"Front Immunol"},{"issue":"5","key":"556_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/acr.22728","volume":"68","author":"S Moghadam-Kia","year":"2016","unstructured":"Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti\u2013melanoma differentiation\u2013associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016;68(5):689\u201394.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"556_CR4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","volume":"51","author":"T Koga","year":"2012","unstructured":"Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S-y, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51(7):1278\u201384.","journal-title":"Rheumatology"},{"issue":"8","key":"556_CR5","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.21992","volume":"65","author":"JC Hall","year":"2013","unstructured":"Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti\u2013melanoma differentiation\u2013associated protein 5\u2013associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. 2013;65(8):1307\u201315.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"556_CR6","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","volume":"95","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95(1):e70\u20138.","journal-title":"Neurology"},{"issue":"11","key":"556_CR7","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1093\/rheumatology\/keac094","volume":"61","author":"J So","year":"2022","unstructured":"So J, So H, Wong VT-L, Ho R, Wu TY, Wong PC-H, et al. Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology. 2022;61(11):4437\u201344.","journal-title":"Rheumatology"},{"issue":"1","key":"556_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-023-03100-z","volume":"25","author":"H Wang","year":"2023","unstructured":"Wang H, Chen X, Du Y, Wang L, Wang Q, Wu H, et al. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res Therapy. 2023;25(1):1\u201310.","journal-title":"Arthritis Res Therapy"},{"issue":"7","key":"556_CR9","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1148\/rg.2015140334","volume":"35","author":"N Sverzellati","year":"2015","unstructured":"Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King Jr TE, Travis WD. American thoracic society\u2013European respiratory society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographics. 2015;35(7):1849\u201371.","journal-title":"Radiographics"},{"issue":"Supplement1","key":"556_CR10","first-page":"keab247","volume":"60","author":"JZ Low","year":"2021","unstructured":"Low JZ, Chua CG, Lim W-Y, Koh LW, Manghani M. P153 characteristics of anti-melanoma differentiation-associated gene 5 positive dermatomyositis in Singapore. Rheumatology. 2021;60(Supplement1):keab247.","journal-title":"Rheumatology"},{"issue":"2","key":"556_CR11","first-page":"309","volume":"41","author":"E Tiniakou","year":"2023","unstructured":"Tiniakou E, Mecoli CA, Kelly W, Albayda J, Paik JJ, Adler BL, et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population. Clin Exp Rheumatol. 2023;41(2):309\u201315.","journal-title":"Clin Exp Rheumatol"},{"key":"556_CR12","doi-asserted-by":"crossref","unstructured":"Li Y, Li Y, Wu J, Miao M, Gao X, Cai W et al. Predictors of poor outcome of anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis. Journal of Immunology Research. 2020;2020.","DOI":"10.1155\/2020\/2024869"},{"key":"556_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1590\/abd1806-4841.20186803","volume":"93","author":"IBP Borges","year":"2018","unstructured":"Borges IBP, Silva MG, Shinjo SK. Prevalence and reactivity of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) autoantibody in Brazilian patients with dermatomyositis. An Bras Dermatol. 2018;93:517\u201323.","journal-title":"An Bras Dermatol"},{"key":"556_CR14","doi-asserted-by":"publisher","first-page":"1286973","DOI":"10.3389\/fimmu.2024.1286973","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Lv C, You H, Xu L, Yuan F, Li J, et al. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model. Front Immunol. 2024;15:1286973.","journal-title":"Front Immunol"},{"key":"556_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1183\/16000617.0105-2021","volume":"30","author":"L Kawano-Dourado","year":"2021","unstructured":"Kawano-Dourado L, Glassberg MK, Assayag D, Borie R, Johannson KA. Sex and gender in interstitial lung diseases. Eur Respiratory Rev. 2021;30:162.","journal-title":"Eur Respiratory Rev"},{"issue":"10","key":"556_CR16","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/acr.21728","volume":"64","author":"H Cao","year":"2012","unstructured":"Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti\u2013melanoma differentiation\u2013associated gene 5 antibody. Arthritis Care Res. 2012;64(10):1602\u201310.","journal-title":"Arthritis Care Res"},{"key":"556_CR17","doi-asserted-by":"publisher","first-page":"1319957","DOI":"10.3389\/fimmu.2023.1319957","volume":"14","author":"H de Boysson","year":"2024","unstructured":"de Boysson H, Cuchet M, Cassius C, Cuchet P, Agard C, Audemard-Verger A, et al. Disease patterns and specific trajectories of anti-MDA5-related disease: a multicentre retrospective study of 70 adult patients. Front Immunol. 2024;14:1319957.","journal-title":"Front Immunol"},{"issue":"9","key":"556_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713\u20139.","journal-title":"Rheumatology"},{"issue":"4","key":"556_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","volume":"147","author":"Y Hamaguchi","year":"2011","unstructured":"Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391\u20138.","journal-title":"Arch Dermatol"},{"issue":"8","key":"556_CR20","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/acr.21985","volume":"65","author":"Z Chen","year":"2013","unstructured":"Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti\u2013melanoma differentiation\u2013associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65(8):1316\u201324.","journal-title":"Arthritis Care Res"},{"key":"556_CR21","doi-asserted-by":"crossref","unstructured":"Sontheimer RD. MDA5 autoantibody\u2014another indicator of clinical diversity in dermatomyositis. Annals Translational Med. 2017;5(7).","DOI":"10.21037\/atm.2017.03.94"},{"issue":"1","key":"556_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10067-023-06816-0","volume":"43","author":"L Cheng","year":"2024","unstructured":"Cheng L, Xu L, Xu Y, Yuan F, Li J, Wu M, et al. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases. Clin Rheumatol. 2024;43(1):339\u201347.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"556_CR23","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","volume":"60","author":"A Xu","year":"2021","unstructured":"Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, et al. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease. Rheumatology. 2021;60(7):3343\u201351.","journal-title":"Rheumatology"},{"issue":"2","key":"556_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3899\/jrheum.220139","volume":"50","author":"C Lv","year":"2023","unstructured":"Lv C, You H, Xu L, Wang L, Yuan F, Li J, et al. Coexistence of anti-ro52 antibodies in anti-mda5 antibody\u2013positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk. J Rhuematol. 2023;50(2):219\u201326.","journal-title":"J Rhuematol"},{"issue":"6","key":"556_CR25","doi-asserted-by":"publisher","first-page":"e0286956","DOI":"10.1371\/journal.pone.0286956","volume":"18","author":"F Dong","year":"2023","unstructured":"Dong F, Zheng L, An W, Xue T, Zhong X. A meta-analysis of the clinical significance of neutrophil-to-lymphocyte ratios in interstitial lung disease. PLoS ONE. 2023;18(6):e0286956.","journal-title":"PLoS ONE"},{"issue":"1","key":"556_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13075-023-03100-z","volume":"25","author":"H Wang","year":"2023","unstructured":"Wang H, Chen X, Du Y, Wang L, Wang Q, Wu H, et al. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res Therapy. 2023;25(1):127.","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"556_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.42308","volume":"75","author":"L Xu","year":"2023","unstructured":"Xu L, You H, Wang L, Lv C, Yuan F, Li J, et al. Identification of three different phenotypes in anti\u2013melanoma differentiation\u2013associated gene 5 antibody\u2013positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease. Arthritis Rheumatol. 2023;75(4):609\u201319.","journal-title":"Arthritis Rheumatol"},{"key":"556_CR28","doi-asserted-by":"crossref","unstructured":"Xie H, Zhang D, Wang Y, Shi Y, Yuan Y, Wang L, et al. editors. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review. Seminars in Arthritis and Rheumatism; 2023: Elsevier.","DOI":"10.1016\/j.semarthrit.2023.152231"},{"issue":"7","key":"556_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1164\/rccm.200804-550OC","volume":"178","author":"JT Cronkhite","year":"2008","unstructured":"Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in Familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(7):729\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"556_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/mr\/road042","volume":"34","author":"B Yang","year":"2024","unstructured":"Yang B, Liu S, Qian Z, Tong Z. Predicting the death of patients with anti-melanoma differentiation\u2013associated protein-5-positive dermatomyositis-associated interstitial lung disease: A systematic review and meta-analysis. Mod Rheumatol. 2024;34(3):541\u201350.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"556_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti\u2013melanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis. Arthritis Rheumatol. 2020;72(3):488\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"556_CR32","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1093\/rheumatology\/keaa123","volume":"59","author":"M Shirakashi","year":"2020","unstructured":"Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology. 2020;59(11):3284\u201392.","journal-title":"Rheumatology"},{"issue":"9","key":"556_CR33","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","volume":"61","author":"L-M Wang","year":"2022","unstructured":"Wang L-M, Yang Q-H, Zhang L, Liu S-Y, Zhang P-P, Zhang X, et al. Intravenous Immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology. 2022;61(9):3704\u201310.","journal-title":"Rheumatology"},{"issue":"8","key":"556_CR34","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American college of rheumatology (ACR)\/American college of chest physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1182\u2013200.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"556_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/art.42150","volume":"74","author":"H So","year":"2022","unstructured":"So H, So J, Lam TTO, Wong VTL, Ho R, Li WL, et al. Performance of the 2017 European alliance of associations for rheumatology\/american college of rheumatology classification criteria in patients with idiopathic inflammatory myopathy and anti\u2013melanoma differentiation\u2013associated protein 5 positivity. Arthritis Rheumatol. 2022;74(9):1588\u201392.","journal-title":"Arthritis Rheumatol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00556-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:44:12Z","timestamp":1757432652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["556"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00556-1","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki. Ethical approval was granted by the Research Ethics Committee of the Faculty of Medicine Ramathibodi Hospital, Mahidol University (COA no. MURA2023\/109). The committee approved the use of patient samples and data for publishing this study. Individual subject informed consent was waived due to the retrospective nature of the study and no prospective engagement with subjects or their legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the ICMJE Uniform Disclosure Form. T. Petnak, T. Suwatanapongched, C. Nitiwarangkul and P. Ngamjanyaporn received honoraria from Boehringer Ingelheim for past lectures on idiopathic pulmonary fibrosis, connective tissue-related ILD, or progressive pulmonary fibrosis. However, these activities are unrelated to the content of the submitted manuscript and have been disclosed. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}